| abstract |
This invention provides a class of androgen receptor target agents (ARTA). The agents define a new subclass of compounds that are selective androgen receptor (SARM) modulators. Several of the SARM compounds have been found to have an unexpected anabolic and androgenic activity of a non-steroidal ligand for the androgen receptor. Other SARM compounds have been found to have an unexpected antiandrogenic activity of a non-steroidal ligand for the androgen receptor. SARM compounds, either alone or as a composition, are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Reduction in Older Men (ADAM), such as fatigue, depression, reduced libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, loss of hair, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostatic hyperplasia, alterations in mood and knowledge and prostate cancer; c) treatment of conditions associated with Androgen Reduction in Women (ADIF), such as sexual dysfunction, reduced sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in knowledge and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and / or prevention of chronic and / or acute muscular waste conditions; e) prevention and / or treatment of dry eye conditions; f) oral androgen replacement therapy; and / or g) reduction of the incidence of, termination or cause of a regression of prostate cancer. |